261 related articles for article (PubMed ID: 15276712)
1. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
4. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
9. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
10. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Xia XD; Dai YR; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
[No Abstract] [Full Text] [Related]
11. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
12. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
15. PDE4 inhibitors in COPD--a more selective approach to treatment.
Vignola AM
Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
[TBL] [Abstract][Full Text] [Related]
16. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Kerstjens HA; Timens W
Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456
[No Abstract] [Full Text] [Related]
18. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
19. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast: a selective phosphodiesterase 4 inhibitor.
Christie P
Drugs Today (Barc); 2005 Oct; 41(10):667-75. PubMed ID: 16389409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
